NHLBI Regional Innovation Conference San Francisco
Tuesday September 10, 2013 | Genentech Hall @ UCSF
This conference brings together small businesses, angel investors, venture capitalists, strategic partners, and business leaders from the biotech and pharmaceutical industries. It will feature presentations by top NHLBI SBIR- funded companies with innovative technologies on the brink of commercialization, an expert panel of investors, and opportunities for partnering and networking. Information about the NHLBI Office of Translational Alliances and Coordination, changes in the SBIR/STTR program re-authorization, and other funding opportunities and resources will be presented. NHLBI staff will be available to provide advice to applicants and awardees.
The NHLBI provides global leadership for research, training, and education to promote the prevention and treatment of heart, lung, blood, and sleep diseases and disorders and to enhance the health of all individuals so that they can live longer and more fulfilling lives.
New Program Feature!
Want to maximize your time at the conference? Partnering software will be available so that one-on-one meetings will be easy to schedule and manage!
9:00 - 10:00 a.m. | Registration & Partnering
10:00 - 10:15 a.m. | Welcome Remarks
10:15 - 10:30 a.m. | NHLBI Presentation
10:30 - 10:45 a.m. | Aronora
10:45 - 11:00 a.m. | Genomics USA
11:00 - 11:15 a.m. | Kestrel Labs
11:15 - 12:20 p.m. | Lunch & Partnering
12:20 - 12:35 p.m. | NHLBI Presentation
12:35 - 12:50 p.m. | Nortis
12:50 - 1:05 p.m. | Silicon BioDevices (SBD)
1:05 - 1:20 p.m. | Syntrix Biosystems
1:20 - 1:50 p.m. | Partnering Break
1:50 - 3:20 p.m. | Investor Panel
3:20 - 3:35 p.m. | Closing Remarks
3:35 - 5:00 p.m. | Reception & Partnering
Afasci, Astraea Therapeutics, BetaStem Therapeutics, Cylerus, DRVision, ELEX Biotech, Gamma Therapeutics, HeartVista, Klein Buendel, Nanoshell Company, NuvOx, PLASALUS, Sharklet Technologies (STI), VPDiagnostics
Stephen Flaim, Special Advisor, NHLBI & Member, Tech Coast Angels SD (Emcee & Moderator)
Flaim holds a doctorate in Human Physiology and Pharmacology from the UC Davis. He held faculty positions in Medicine and Physiology at the Pennsylvania State University College of Medicine and senior management roles at the J&J Pharmaceutical Research Institute, the Squibb Institute for Medical Research, Alliance Pharmaceutical Corporation, Trega Biosciences and Galileo Pharmaceuticals. Flaim is Founder & President of Flaim Partners Consulting, a Fellow of the American College of Cardiology, the AHA, the American College of Clinical Pharmacology, and the Royal Society of Medicine. He is a board member of Pivotal Biosciences and AnaBios Corporation, Chairman of the Board for Leading Biosciences, on the Editorial Board of the Journal of Pharmacology and Experimental Therapeutics, a Technology and Business advisor to the William J. von Liebig Center for Entrepreneurism and Technology Advancement at UCSD, Chairman of TCA and Chairman of the John G. Watson Foundation. Flaim is Cofounder & CEO of CardioCreate and Chairman & CEO of OncoFluor. Flaim is Special Advisor to the Office of Translational Alliances and Coordination in the Division of Extramural Research Activities, NHBLI of the NIH.
Allan May, Founder & Chairman, Life Science Angels
Allan is a founder of Life Science Angels (www.lifescienceangels.com ), the largest angel organization in the U.S. focused solely on early stage medical device and life science start-ups, and comprised solely of high net worth individuals from the medical device or biotech fields. LSA has invested over $35M in 40 startups and achieved 7 positive exits to date. In 2011, Allan launched the Life Science Angel Network, a consortium of 15 angel groups throughout the United States, to focus on increasing the syndication and capitalization of highly vetted healthcare startups. Since 1995, Allan has been founder, Chairman, CEO, or investor in over 50 medtech, biotech, and diagnostic startups. He has led the business section of Singularity University’s FutureMed program, and speaks frequently at universities, conferences and government programs on trends and developments affecting early stage biotech and medtech investing. Allan is also a member of the boards of the Open Medicine Institute and Vascular Cures, and a member of the advisory board of the UCSF Entrepreneurship Center.
Gregory Naeve, Rinat Lead and Head of Strategic Research Partnerships, San Francisco External R&D Innovation, Worldwide Research & Development, Pfizer Inc.
Dr. Naeve is currently the Rinat Lead and Head of Pfizer’s San Francisco office for Strategic Research Partnerships in the External Research, Development, & Innovation unit. In this role Greg is responsible for liaising with Pfizer Scientists to identify and institute strategic partnerships that address internal technology and pipeline needs. Prior to Pfizer he worked as a venture capitalist with the San Francisco-based life science venture fund, The Column Group, a firm focused on creating biotechnology companies to develop novel therapeutics and technologies. Prior to that he was the President and Chief Scientific Officer of Parallax Biosystems, a company he co-founded to develop a molecular detection platform with applications in pre-clinical drug discovery and diagnostics. Before Parallax he held positions at Neurocrine Biosciences and Amgen working to develop new therapies for neurodegenerative disorders. He received his Ph.D. in Biochemistry from the University of Southern California.
Andrew Schwab, Managing Partner, 5AM Ventures
Andrew J. Schwab is a Founder and Managing Partner of 5AM Ventures. Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital. After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx. Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Cleave, DVS, Flexion, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.
FREE (space is limited)
@NHLBI_SBIR | #NHLBIshowcase
Madelaine Holden | email@example.com
NOT AVAILABLE SEPTEMBER 10?
But you still want to meet with an NHLBI representative? Sign up for a 1-on-1 on September 11th at UCSF. Register here.
When & Where
The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.
The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public. It creates and supports a robust, collaborative research infrastructure in partnership with private and public organizations, including academic institutions, industry, and other government agencies. The Institute collaborates with patients, families, health care professionals, scientists, professional societies, patient advocacy groups, community organizations, and the media to promote the application of research results and leverage resources to address public health needs. The NHLBI also collaborates with international organizations to help reduce the burden of heart, lung, and blood diseases worldwide.